Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
245 EUR | -0.08% |
|
-2.62% | +15.68% |
09:51am | Roche: share price rises following successful obesity trial | CF |
08:35am | Roche Obesity Pill Achieves Positive Results in Early-Stage Trial -- Update | DJ |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Sales forecast by analysts have been recently revised upwards.
Weaknesses
- The company's enterprise value to sales, at 3.65 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.68% | 234B | - | ||
+61.53% | 848B | C+ | ||
+34.02% | 627B | B | ||
-3.66% | 363B | C+ | ||
+15.06% | 318B | B- | ||
+9.18% | 299B | C+ | ||
+15.35% | 225B | B- | ||
+15.67% | 179B | C+ | ||
+2.47% | 167B | C+ | ||
+1.87% | 125B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ROG Stock
- RHO Stock
- Ratings Roche Holding AG